Racing to save lives and fighting the PR battle
August 6, 2009Medical Communications, Research and Development Vaccine, clinical trials, public relations
Vaccine companies are working round the clock to develop and manufacture a vaccine for the H1N1 pandemic flu, and are …
Vasella targeted by animal rights activists
August 6, 2009Research and Development, Sales and Marketing Animal tests, Novartis, Vasella
Animal rights activists are believed to be behind two attacks on Novartis chief executive Daniel Vasella. The first attack came …
Afinitor approved in EU
August 6, 2009Research and Development, Sales and Marketing Afinitor, Cancer, Europe, Novartis
Novartis’ new kidney cancer drug Afinitor (everolimus) has been approved in the EU for use when products such as Sutent …
US approval for Onglyza
August 6, 2009Research and Development, Sales and Marketing AZ, BMA, diabetes
Adult type II diabetes treatment Onglyza has been approved by the US Food and Drug Administration. Co-marketed by AstraZeneca and …
FDA blocks Teva from selling vet drugs and warns Apotex
August 6, 2009Manufacturing and Production Apotex, FDA, Teva
The FDA’s clampdown on quality standards continues apace, with Teva’s animal health unit in Missouri and an Apotex plant in …
Industry working group to look at UK digital marketing
August 6, 2009Medical Communications, Sales and Marketing digi, pm society
The PM Society has set up an industry working group to bring some much-needed clarity to the uncharted waters of …
Kennedy and Drayson: parallel plans to boost UK’s innovation agenda
August 5, 2009Research and Development NICE, healthcare
1: The Office of Life Science’s ‘Blueprint’The first to be launched was the ‘Blueprint’ – a new strategic vision aiming …
Lab specialist Celsis set for private ownership
August 5, 2009Manufacturing and Production Celsis
UK laboratory equipment and services company Celsis looks set to be taken into private ownership after its management agreed to …
Boehringer’s lung cancer candidate enters phase III
August 5, 2009Research and Development, Sales and Marketing Boehringer, Cancer
Boehringer Ingelheim is to enter phase III studies with a candidate to treat a subset of patients with non-small cell …
Centocor launches online arthritis talk show
August 4, 2009Medical Communications, Sales and Marketing Centacor, RA, US, digi
An online talk show for rheumatoid arthritis patients has been launched in the US with the aim of raising awareness …
ICR conference moves to London
August 4, 2009Business Services, Research and Development Conference, ICR
The Institute of Clinical Research (ICR) is to hold its next annual spring conference and exhibition on 19-20 April at …
Bayer has solution for solvent shortage in pharma
August 4, 2009Manufacturing and Production Bayer
German chemical company Bayer says it could have a solution to help ease the current shortage of acetonitrile, a solvent …
Covance lifted by $145m Merck deal
August 4, 2009Research and Development CRO, Covance
Covance's late-stage development services unit helped the contract research organisation to a 7% increase in second quarter net revenues, ahead …
Avastin gets US approval in kidney cancer
August 4, 2009Research and Development, Sales and Marketing Roche, US, avastin
Roche's rising star Avastin has won US approval to treat the most common type of kidney cancer, the latest in …
UCB in ‘dynamic mode’ as work begins at new biologics research centre
July 31, 2009Research and Development UCB, biologics
UCB has opened its new biologics research centre in the UK, marking an investment of £25 million for the growing …
Crestor drives positive results for AZ
July 31, 2009Sales and Marketing AZ, Crestor
AstraZeneca delivered a solid second quarter performance thanks to US delays to generic rivals and strong Crestor sales. The results …
Reshuffle at the top as Mylan deals with quality queries
July 31, 2009Manufacturing and Production, Research and Development Mylan
US pharmaceutical firm Mylan has promoted chief operating officer Heather Bresch to the post of president as it rides a …
Merck Serono asks EMEA to re-think Erbitux rejection
July 30, 2009Research and Development, Sales and Marketing Cancer, EMEA, Erbitux, Europe, Merck Serono
Merck Serono is to appeal against the European rejection of Erbitux as a lung cancer treatment.Erbitux has been rejected as …
Sanofi makes bold promises with Q2 results
July 30, 2009Sales and Marketing Sanofi-Aventis, patents
Sanofi-Aventis has promised its 2013 sales will at least match those the company made last year, despite facing huge and …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
